Literature DB >> 29146013

[Chronic histiocytic intervillositis: Diagnosis and management].

A Mekinian1, N Costedoat-Chalumeau2, L Carbillon3, A Coulomb-L'Hermine4, V Le Guern2, A Masseau5, E Lazaro6, J Cohen7, M Bornes7, G Kayem8, O Fain9.   

Abstract

Chronic intervillositis is a rare condition, which is associated with severe obstetrical outcome and high recurrence rate. Obstetrical adverse events are intrauterine growth restriction, recurrent early miscarriages, intrauterine deaths and prematurity by placental insufficiency. The determination of the extension and the intensity of the chronic intervillositis are not currently standardized. High rates of recurrence have been described, but actually there is no reliable predictive biomarker. No treatment is currently validated, but the use of immunomodulatory drugs could be justified by the possible autoimmune or allo-immune origin. The treatment should be particularly discussed in patients with recurrent and severe obstetrical adverse events and in the presence of severe and massive histological lesions.
Copyright © 2017 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Associated autoimmune diseases; Chronic intervillositis; Intervillites; Maladies associées; Outcome; Pronostic; Traitement; Treatment

Mesh:

Substances:

Year:  2017        PMID: 29146013     DOI: 10.1016/j.revmed.2017.10.422

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  1 in total

1.  Chronic histiocytic intervillositis (CHI): current treatments and perinatal outcomes, a systematic review and a meta-analysis.

Authors:  Laurel Moar; Chloe Simela; Surabhi Nanda; Andreas Marnerides; Mudher Al-Adnani; Catherine Nelson-Piercy; Kypros H Nicolaides; Panicos Shangaris
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.